Core Insights - The new centralized procurement rules for pharmaceuticals in China allow medical institutions to report quantities based on specific drug brands, enhancing the alignment between clinical demand and supply [1][2] - A total of 46,000 medical institutions participated in this procurement, with 77% of reported quantities specified by brand [1] - The procurement process emphasizes clinical opinions, excluding high-risk drugs and focusing on pediatric medications with adjusted pricing rules [2] Group 1 - The new procurement rules aim to maintain clinical medication habits, with most hospitals opting to report quantities by brand to ensure continuity in treatment [1][2] - The procurement encourages companies with high clinical recognition to participate, allowing for better fulfillment of clinical needs even if their initial bids do not qualify [1][2] - The inclusion of special antibiotics in the procurement process has shifted the competitive volume from 60%-80% to 40%-60%, granting hospitals more autonomy in selecting these critical medications [2] Group 2 - The procurement process for heparin involved extensive visits to manufacturers to ensure that price reductions do not compromise clinical supply [3] - Quality control standards for bidding companies have been raised, requiring at least two years of production experience and compliance with Good Manufacturing Practices (GMP) [3][4] - Preference is given to companies with stable quality and higher reported quantities, ensuring that the procurement process favors reliable suppliers [4]